AnaptysBio, Inc. Common Stock (ANAB)
AnaptysBio, Inc. (ANAB) is a biotechnology company focused on developing therapeutic antibodies for immune-related conditions. Founded in 2005 and based in San Diego, California, the company utilizes innovative antibody discovery and engineering technologies to create novel biologics targeting inflammatory and immuno-oncology diseases. Its pioneering platform aims to address unmet medical needs through antibody therapeutics.
Company News
Multiple health care stocks experienced significant price movements during Monday's after-market trading session, with some companies seeing notable gains while others experienced declines.
The psoriasis pipeline has several drugs in mid- and late-stage development, including Imsidolimab, TAK-279, and Sonelokimab, which are expected to positively impact the market. The treatment landscape is expanding with new therapies from various companies.
AnaptysBio, a clinical-stage biotech company, has seen its stock price rise recently. A positive research note from Guggenheim analyst Yatin Suneja, who reiterated a buy rating and $75 price target, cites an upcoming phase 2 clinical trial readout for the company's atopic dermatitis drug and Sanofi's financial involvement as reasons for optimism.
Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.